PseudoWell
PseudoWell, licence 80096787: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- NasalWell, SinusWell, SudaWell, Well-Nasal
- Licence holder
- 110 Formulas Corp.
- NPN or DIN-HM
- 80096787
- Status
- Inactive licence
- Licence date
- 23 January 2020
- Revision date
- 29 August 2022
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Cellulose, Povidone, Dioxyde de titane, Hypromellose, Encre bleue comestible, Cire de Candelilla, Poly(éthylène glycol), Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 12.0 Année(s) | 1.0 Capsule | minimum: 1.0 Tous les jours ; maximum: 4.0 Tous les jours |
Uses authorised in Canada
Used as a decongestant/to relieve nasal congestion (due to hay fever/allergic rhinitis /allergies/sinusitis/the common cold/flu). Nasal decongestant.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Stop use in case of restlessness, irritability, dizziness, tremor, severe headache, insomnia, loss of appetite, nausea, rapid heartbeat, shortness of breath and/or disturbance of urination.
- Contre-indications
Do not use this product if you are taking, or have taken monoamine oxidase inhibitors in the past two weeks.
- Précautions et mises en garde
Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you are pregnant or breastfeeding. Consult a health care practitioner/health care provider/health care professional/doctor/ physician if symptoms persist or worsen. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you are taking medication and/or natural health products for allergy symptoms, asthma, cough/cold or weight control. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you are taking other products which contain caffeine, ephedrine, phenylpropanolamine or pseudoephedrine. Consult a health care practitioner/health care provider/health care professional/doctor/ physician prior to use if you have cardiovascular disease, diabetes, difficulty in urination due to prostate enlargement, glaucoma, thyroid problems, seizure disorders or a pre-existing psychiatric condition. Keep out of reach of children.
Source
Official Health Canada record, licence 80096787
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.